Research map: Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms

Back to the article

Papers in this map

  1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis · Brian G. Feagan · 2013 · 2918 citations · Cited by this paper
  2. A case report of adult congenital intestinal malrotation · 2025 · Related
  3. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD · Dan Turner · 2021 · 2888 citations · Cited by this paper
  4. The challenging diagnosis of sinistral portal hypertension in a patient with liver cirrhosis: a case report and literature review · 2026 · Related
  5. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease · William J. Sandborn · 2013 · 2734 citations · Cited by this paper
  6. Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis · 2025 · Related
  7. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease · Brian G. Feagan · 2016 · 1860 citations · Cited by this paper
  8. Malaria and malnutrition in tribal areas of India: implications for paediatric health · 2025 · Related
  9. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis · William J. Sandborn · 2017 · 1774 citations · Cited by this paper
  10. Helicobacter pylori infection in gastric cancer patients in French Guiana: a hospital-based study (2018–2023) · 2026 · Related
  11. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis · Bruce E. Sands · 2019 · 1226 citations · Cited by this paper
  12. MASH and the race for liver antifibrotics · 2026 · Related
  13. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics · Wenhui Wang · 2008 · 965 citations · Cited by this paper
  14. Case Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies · 2025 · Related
  15. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials · Silvio Danese · 2022 · 641 citations · Cited by this paper
  16. New-onset diabetes as an emerging risk group for early detection of pancreatic cancer: current evidence, clinical challenge, and future directions · 2026 · Related
  17. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis · William J. Sandborn · 2021 · 566 citations · Cited by this paper
  18. Ischemic proctitis caused by a superior rectal arteriovenous fistula: a case report and literature review · 2026 · Related
  19. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease · Edward V. Loftus · 2023 · 476 citations · Cited by this paper
  20. Recent advances, comparative performance, and data requirements of artificial intelligence-assisted technologies for the diagnosis of gastric cancer · 2026 · Related
  21. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial · Brian G. Feagan · 2021 · 458 citations · Cited by this paper
  22. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials · Geert D’Haens · 2022 · 426 citations · Cited by this paper
  23. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies · William J. Sandborn · 2023 · 366 citations · Cited by this paper
  24. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis · Geert D’Haens · 2023 · 356 citations · Cited by this paper
  25. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial · Marc Ferrante · 2022 · 342 citations · Cited by this paper
  26. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases · Konstantinos Papamichael · 2019 · 340 citations · Cited by this paper
  27. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis · William J. Sandborn · 2019 · 330 citations · Cited by this paper
  28. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease · Maria Rosario · 2015 · 268 citations · Cited by this paper
  29. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease · Omoniyi J. Adedokun · 2018 · 256 citations · Cited by this paper
  30. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease · Robert J. Battat · 2017 · 241 citations · Cited by this paper
  31. Long-term Efficacy of Vedolizumab for Crohn’s Disease · Severine A.R.A. Vermeire · 2016 · 216 citations · Cited by this paper
  32. Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study · Asit Parikh · 2011 · 212 citations · Cited by this paper
  33. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease · Adam S. Cheifetz · 2021 · 206 citations · Cited by this paper
  34. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study · William J. Sandborn · 2022 · 203 citations · Cited by this paper
  35. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis · Laurent Peyrin‐Biroulet · 2018 · 180 citations · Cited by this paper
  36. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial · Severine A.R.A. Vermeire · 2021 · 175 citations · Cited by this paper
  37. Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease · Maria Rosario · 2017 · 161 citations · Cited by this paper
  38. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases · Erwin Dreesen · 2018 · 158 citations · Cited by this paper
  39. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study · Neil Chanchlani · 2024 · 156 citations · Cited by this paper

Source: OpenAlex (CC0)